Skip to main content
Download PDF

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Molecular Cancer volume 20, Article number: 21 (2021) Cite this article

The Original Article was published on 07 January 2021

Correction to: Mol Cancer (2021) 20:12

https://doi.org/10.1186/s12943-020-01306-2

Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

Reference

  1. Cheli Y, Tulic MK, El Hachem N, et al. ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer. 2021;20:12. https://doi.org/10.1186/s12943-020-01306-2.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Corine Bertolotto and Robert Ballotti contributed equally to this work.

Authors and Affiliations

  1. Université Nice Côte d’Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000, Nice, France

    Yann Cheli, Nicolas Nottet, Thomas Strub, Karine Bille, Guillaume E. Beranger, Corine Bertolotto & Robert Ballotti

  2. Université Nice Côte d’Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000, Nice, France

    Meri K. Tulic, Guillaume E. Beranger & Thierry Passeron

  3. Laboratory of Cancer Signaling, University of Liège, Liège, Belgium

    Najla El Hachem & Pierre Close

  4. Université Nice Côte d’Azur, INSERM, U1065, Team2 Cell death, differentiation and cancer, 06000, Nice, France

    Arnaud Jacquel

  5. Université Nice Côte d’Azur, INSERM, U1065, Imaging platform, 06000, Nice, France

    Maeva Gesson

  6. CHU NICE, Département de Dermatologie, 06000, Nice, France

    Alexandra Picard-Gauci, Henri Montaudié & Thierry Passeron

Authors
  1. Yann Cheli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meri K. Tulic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Najla El Hachem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicolas Nottet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arnaud Jacquel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maeva Gesson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas Strub
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karine Bille
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alexandra Picard-Gauci
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Henri Montaudié
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Guillaume E. Beranger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Thierry Passeron
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Pierre Close
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Corine Bertolotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Robert Ballotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yann Cheli.

Supplementary Information

12943_2021_1319_MOESM1_ESM.pdf

Additional file 1.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cheli, Y., Tulic, M.K., El Hachem, N. et al. Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. Mol Cancer 20, 21 (2021). https://doi.org/10.1186/s12943-021-01319-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12943-021-01319-5

Molecular Cancer

ISSN: 1476-4598